Orphaned Vaccines
Sometimes viewing a complex issue in its most simplistic form can help us to understand where a problem lies. HIV is a virus that...
4 CROI Briefs
Another year of the Conference on Retroviruses and Opportunistic Infections (CROI 2016) has come to pass. Here are a few less publicized but important...
Vpu Inhibitor Candidate
BIT225 is a new type of antiviral called a Vpu inhibitor, which researchers are investigating to treat both HIV and HIV/hepatitis C (HCV) co-infection....
HTVN 702: Vaccine Candidate
Step Forward
Vaccine candidates like HTVN 702 are needed to build momentum
by Jeannie Wraight
If current HIV diagnoses rates persist, about 1 in 2 black men...
HIV Remission Studies & Starting ARVs Early
Step by Step
At CROI 2017, HIV remission studies focus on early antiretroviral therapy initiation
by Jeannie Wraight
This year marked the 24th annual Conference on Retroviruses...
Targeting HIV Reservoirs
Hiding Place
One focus of the amfAR 2016 CURE Summit targeted HIV reservoirs
by Jeannie Wraight
This year, amfAR marked World AIDS Day with the 2016 HIV...
RIVER Study: Kick & Kill Vaccine Strategy
RIVER Dry
Kick and kill strategy study yields disappointing results
by Jeannie Wraight
Latent HIV resides in cells in blood and tissue which we collectively call the...
Post-Treatment Controllers & HIV Treatment
Control Issues
What can post-treatment controllers tell us about HIV care and treatment?
by Jeannie Wraight
In order to keep their virus suppressed, most people living with...
Moderna Starts HIV Vaccine Research
Opening New Doors
Moderna to Begin HIV Vaccine Research Using COVID-19 Technology
by Chip Alfred
Based on the success of its COVID-19 vaccine, Moderna, a biotech company...
Counting Cures
Destination: Cure by Jeannie Wraight
Counting Cures
Before we start tallying “cures,” let’s strive to define what we mean by “cured?”
Several months ago a media frenzy...